[CAS NO. 40828-46-4] Suprofen
PRODUCTS SPECIFICATIONS [40828-46-4]
DESCRIPTION [40828-46-4]
Overview
| MDL | MFCD00079572 |
|---|---|
| Molecular Weight | 260.31 |
| Molecular Formula | C14H12O3S |
| SMILES | O=C(O)C(C)C1=CC=C(C(C2=CC=CS2)=O)C=C1 |
Summary
Suprofen (TN-762) is a non-steroidal anti-inflammatory drug (NSAID).
IC50 & Target
PGE synthase [1] .
In Vitro
Suprofen (TN-762) is an NSAID. Suprofen (TN-762) is an ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. suprofen was clinically effective but the differential suppression of prostanoids favors 200mg which spares 6-keto PGF1a [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 384.16 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.8416 mL | 19.2079 mL | 38.4157 mL |
| 5 mM | 0.7683 mL | 3.8416 mL | 7.6831 mL |
| 10 mM | 0.3842 mL | 1.9208 mL | 3.8416 mL |
References
- [1] Yeadon, A., et al., Suprofen. An overview of long-term safety. Pharmacology, 1983. 27 Suppl 1: p. 87-94.
- [2] Dawood, M.Y. and F.S. Khan-Dawood, Differential suppression of menstrual fluid prostaglandin F2a, prostaglandin E2, 6-keto prostaglandin F1a and thromboxane B2 by suprofen in women with primary dysmenorrhea. Prostaglandins Other Lipid Mediat, 2007. 83(1-2
Synonyms